Yuhan(000100) set record quarterly sales and operating profit.
The company said on the 30th that, on a standalone basis, operating profit in the second quarter was 61.4 billion won, up 34.7% from the same period a year earlier, based on preliminary figures.
Sales for the same period rose 10.4% to 614 billion won, and net profit increased 22.1% to 47.6 billion won.
The strong results are seen as reflecting a sharp improvement in profitability as milestone (stepwise license fee) and royalty (running royalty) revenue from the lung cancer drug "Leclaza (ingredient name Lazertinib)" out-licensed to Johnson & Johnson (J&J) in the United States were recognized.
※ This article has been translated by AI. Share your feedback here.